Rigel Pharmaceuticals, Inc. (RIGL)
RIGL moved a median of -0.46% 30 minutes after news, and +0.29% by the close. How RIGL actually reacts to news — the realized, point-in-time move the market made, measured across 281 labeled events over the last three years with zero look-ahead.
RIGL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 43% | 281 |
| 30-min | -0.46% | 42% | 281 |
| 60-min | -0.36% | 42% | 281 |
| to close | +0.29% | 51% | 280 |
| Middle 50% of RIGL reactions | -1.51% to +1.00% |
|---|---|
| Median reaction (30-min) | -0.46% |
| Measured reactions | 281 |
Half of all Rigel Pharmaceuticals, Inc. news events land between -1.51% and +1.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RIGL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 21 | -0.07% | 38% | -1.39% |
| Analyst downgrades | 14 | -0.62% | 43% | -1.11% |
| Rating reiterations | 63 | +0.23% | 56% | +0.30% |
| Price-target raises | 12 | -0.49% | 42% | -1.74% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RIGL ranks against every other measured name →
That’s how RIGL usually reacts — get an email when it moves on news →Email me when RIGL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RIGL's baseline. Nothing else.
Recent RIGL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.92% | -1.07% | |
| Rigel to Participate in Upcoming September Investor Conferences | Press release | PR Newswire | +1.98% | +2.96% | |
| Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer | Press release | PR Newswire | -1.53% | -4.07% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.63% | -4.71% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.63% | -4.71% | |
| Form S-8 RIGEL PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | -1.63% | -4.71% | |
| Rigel Reports Second Quarter 2026 Financial Results | Press release | PR Newswire | -1.63% | -4.71% | |
| Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results | Press release | PR Newswire | -0.24% | +2.72% | |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.69% | +4.67% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -1.17% | |
| Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer | Press release | PR Newswire | -0.90% | -1.44% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -3.18% | |
| Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) | Press release | PR Newswire | +1.71% | +2.02% | |
| Rigel to Present at the Jefferies Global Healthcare Conference | Press release | PR Newswire | -0.27% | +0.99% | |
| Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress | Press release | PR Newswire | +0.93% | -0.28% | |
| Form 8-K RIGEL PHARMACEUTICALS For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +3.22% | |
| Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference | Press release | PR Newswire | -0.14% | -2.12% | |
| Form 8-K RIGEL PHARMACEUTICALS For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.57% | +6.32% | |
| Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer | Press release | PR Newswire | +6.15% | +5.00% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.44% | -7.07% | |
| Form 8-K RIGEL PHARMACEUTICALS For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -2.44% | -7.07% | |
| Rigel Reports First Quarter 2026 Financial Results | Press release | PR Newswire | -2.44% | -7.07% | |
| Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results | Press release | PR Newswire | -0.31% | -0.42% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | -6.10% | |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.49% | +4.53% | |
| Form DEF 14A RIGEL PHARMACEUTICALS For: May 14 | SEC filing · Form DEF | SEC EDGAR | -0.16% | -0.80% | |
| Form DEFA14A RIGEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.16% | -0.80% | |
| Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology | Press release | PR Newswire | +2.67% | +2.93% | |
| Form 10-K RIGEL PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -5.12% | -2.15% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -5.12% | -2.15% | |
| Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | -5.12% | -2.15% | |
| Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update | Press release | PR Newswire | +1.44% | +1.50% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Feb 01 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -2.56% | |
| Rigel Appoints Michael P. Miller to the Board of Directors | Press release | PR Newswire | +0.69% | +1.34% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.22% | -4.08% | |
| Rigel Provides Business Update and 2026 Outlook | Press release | PR Newswire | -3.22% | -4.08% | |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.14% | -9.16% | |
| Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +2.13% | +7.52% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +2.69% | |
| Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition | Press release | PR Newswire | -10.15% | -9.34% | |
| Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | PR Newswire | -0.78% | +0.87% | |
| Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology | Press release | PR Newswire | -0.44% | +1.36% | |
| Rigel to Present at the Jefferies Global Healthcare Conference in London | Press release | PR Newswire | +1.09% | +3.74% | |
| Form 10-Q RIGEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.56% | +8.55% | |
| Form 8-K RIGEL PHARMACEUTICALS For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +3.56% | +8.55% | |
| Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | PR Newswire | +3.56% | +8.55% | |
| Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition | Press release | PR Newswire | -0.38% | -2.94% | |
| Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update | Press release | PR Newswire | +0.67% | -1.01% | |
| Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS | Press release | PR Newswire | -1.95% | -4.93% | |
| Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.93% | +1.78% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RIGL section they belong to.
Where else RIGL is measured.
RIGL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 279 | -0.52% | 36% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rigel Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled RIGL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 281 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of RIGL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RIGL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.